Format

Send to

Choose Destination
Neurogenetics. 2019 May;20(2):73-82. doi: 10.1007/s10048-019-00574-5. Epub 2019 Mar 23.

Celia's encephalopathy and c.974dupG in BSCL2 gene: a hidden change in a known variant.

Author information

1
Thyroid and Metabolic Diseases Unit, Biomedical Research Institute (CIMUS)-IDIS, School of Medicine, Universidade de Santiago de Compostela, Santiago, Spain.
2
Boston Children's Hospital, Harvard University, Cambridge, MA, USA.
3
Servicio de Neurología, Hospital Sant Joan de Déu, Barcelona, Spain.
4
Section of Neuropediatrics, Division of Pediatrics, Hospital Clínico Universitario Virgen de la Arrixaca-IMIB Arrixaca, Murcia, Spain.
5
Division of Endocrinology and Nutrition, Hospital Clínico Universitario de Santiago de Compostela, Santiago, Spain.
6
Division of Nuclear Medicine, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
7
Molecular Imaging and Medical Physics, Universidade de Santiago de Compostela. IDIS, Santiago, Spain.
8
Pediatric Intensive Care Unit, Pediatric Area, Hospital Clínico Universitario de Santiago de Compostela, Santiago, Spain.
9
Anesthesia and Reanimation Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago, Spain.
10
National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
11
Thyroid and Metabolic Diseases Unit, Biomedical Research Institute (CIMUS)-IDIS, School of Medicine, Universidade de Santiago de Compostela, Santiago, Spain. david.araujo@usc.es.
12
Division of Endocrinology and Nutrition, Hospital Clínico Universitario de Santiago de Compostela, Santiago, Spain. david.araujo@usc.es.
13
U.E.T.eM. CIMUS.|, University of Santiago de Compostela, Avda. de Barcelona 3, 15707, Santiago de Compostela, Spain. david.araujo@usc.es.

Abstract

Celia's encephalopathy (progressive encephalopathy with/without lipodystrophy (PELD)) is a childhood neurodegenerative disorder with a fatal prognosis before the age of 10, due to the variant c.985C>T in the BSCL2 gene that causes a cryptic splicing site leading to skipping of exon 7. For years, different authors have reported cases of congenital generalized lipodystrophy due to the variant c.974dupG in BSCL2 associated with neurological manifestations of variable severity, although some of them clearly superimposable to PELD. To identify the molecular mechanisms responsible for these neurological alterations in two patients with c.974dupG. Clinical characterization, biochemistry, and neuroimaging studies of two girls carrying this variant. In silico analysis, PCR amplification, and BSCL2 cDNA sequencing. BSCL2-201 transcript expression, which lacks exon 7, by qPCR in fibroblasts from the index case, from a healthy child as a control and from two patients with PELD, and in leukocytes from the index case and her parents. One with a severe encephalopathy including a picture of intellectual deficiency, severe language impairment, myoclonic epilepsy, and lipodystrophy as described in PELD, dying at 9 years and 9 months of age. The other 2-year-old patient showed incipient signs of neurological involvement. In silico and cDNA sequencing studies showed that variant c.974dupG gives rise to skipping of exon 7. The expression of BSCL2-201 in fibroblasts was significantly higher in the index case than in the healthy child, although less than in the case with homozygous PELD due to c.985C>T variant. The expression of this transcript was approximately half in the healthy carrier parents of this patient. The c.974dupG variant leads to the skipping of exon 7 of the BSCL2 gene and is responsible for a variant of Celia's encephalopathy, with variable phenotypic expression.

KEYWORDS:

BSCL2; Congenital generalized lipodystrophy; Cryptic splicing; Neurodegeneration; PELD

PMID:
30903322
DOI:
10.1007/s10048-019-00574-5

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center